References
- Laughren T. P., et al. Premarketing Safety Evaluation of Psychotropic Drugs. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, R. F. Brian, D. S. Robinson. Raven Press Ltd., New York 1994; 85–215
- O'Neill R. T. Assessment of Safety in Biopharmaceutical Statistics. Biopharmaceutical Statistics for Drug Development, K. E. Peace. Marcel Dekker, New York 1988; 543–570
- Cochran W. G. Planning and Analysis of Observational Studies, L. E. Moses, F. Mosteller. John Wiley & Sons, New York 1983
- Burkhart G. A. Angiotensin Converting Enzyme Inhibitor-Associated Angioedema: Higher Risk in Blacks than Whites, Submitted for publication
- Hammaratrom T., et al. Sedative-Hypnotic Drugs and the Risk of Hip Fracture. Psychopharmacologic Drugs Advisory Committee. May 19, 1992, FDA
- McKeigue P. M., et al. Bendectin and Birth Defects: I. A Meta-Analysis of the Epidemiologic Studies. Teratology 1994; 50: 27–37
- Fleiss J. L., Gross A. J. Meta-Analysis in Epidemiology, with Special Reference to Studies of the Association Between Exposure to Environmental, Tobacco Smoke and Lung Cancer: A Critique. J of Clin Epidemiol. 1991; 44: 127–139
- Greenland S. Quantitative Methods in the Review of Epidemiologic Literature. Epidemiol Rev 1987; 9: 1–30